DK1408109T3 - Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel - Google Patents

Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel

Info

Publication number
DK1408109T3
DK1408109T3 DK02746067T DK02746067T DK1408109T3 DK 1408109 T3 DK1408109 T3 DK 1408109T3 DK 02746067 T DK02746067 T DK 02746067T DK 02746067 T DK02746067 T DK 02746067T DK 1408109 T3 DK1408109 T3 DK 1408109T3
Authority
DK
Denmark
Prior art keywords
protein
aging
cells
screening
aging agent
Prior art date
Application number
DK02746067T
Other languages
Danish (da)
English (en)
Inventor
Fuyuki Ishikawa
Original Assignee
Fuyuki Ishikawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuyuki Ishikawa filed Critical Fuyuki Ishikawa
Application granted granted Critical
Publication of DK1408109T3 publication Critical patent/DK1408109T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating And Analyzing Materials By Characteristic Methods (AREA)
DK02746067T 2001-07-16 2002-07-15 Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel DK1408109T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001215576 2001-07-16
JP2001286412 2001-09-20
PCT/JP2002/007182 WO2003008577A1 (fr) 2001-07-16 2002-07-15 Nouvelles cellules transformees, methode de criblage d'agent anti-vieillissement et agents anti-vieillissement

Publications (1)

Publication Number Publication Date
DK1408109T3 true DK1408109T3 (da) 2008-10-06

Family

ID=26618801

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02746067T DK1408109T3 (da) 2001-07-16 2002-07-15 Hidtil ukendt fremgangsmåde til induktion af cellesenescens og fremgangsmåde til screening for et antiældningsmiddel

Country Status (8)

Country Link
US (1) US7291499B2 (fr)
EP (1) EP1408109B1 (fr)
JP (1) JPWO2003008577A1 (fr)
AT (1) ATE400649T1 (fr)
CA (1) CA2454873C (fr)
DE (1) DE60227524D1 (fr)
DK (1) DK1408109T3 (fr)
WO (1) WO2003008577A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011045334A (ja) * 2009-08-28 2011-03-10 Kyushu Univ 細胞老化関連因子
FR2971792B1 (fr) * 2011-02-18 2017-06-23 Isp Investments Inc Methode in vitro pour identifier des agents modulateurs de la senescence cellulaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09271395A (ja) 1996-04-02 1997-10-21 Nippon Zoki Pharmaceut Co Ltd 内皮細胞を用いたスクリーニング法
JP2002515744A (ja) 1996-05-20 2002-05-28 シグナル ファーマシュウティカルズ，インコーポレイテッド マイトジェン活性化プロテインキナーゼｐ３８―２およびその使用方法
JP2000515749A (ja) 1996-08-07 2000-11-28 ザ ジェネラル ホスピタル コーポレーション Ａｇｅ―１ポリペプチド及び関連分子並びに方法
IL129222A0 (en) 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
EP1109918B1 (fr) 1998-06-24 2006-10-04 University of Dundee Proteine kinases activees par des signaux mitogenes et le stress comprenant deux domaines kinase et leurs utilisations
CA2335595A1 (fr) 1998-06-29 2000-01-06 The Regents Of The University Of California Antagonistes bifonctionnels des cascades d'activation des kinases sensibles aux cytokines et technique permettant de les utiliser comme anti-inflammatoires

Also Published As

Publication number Publication date
CA2454873C (fr) 2013-10-01
EP1408109B1 (fr) 2008-07-09
ATE400649T1 (de) 2008-07-15
DE60227524D1 (de) 2008-08-21
CA2454873A1 (fr) 2003-01-30
EP1408109A4 (fr) 2005-02-16
US7291499B2 (en) 2007-11-06
JPWO2003008577A1 (ja) 2004-11-11
WO2003008577A1 (fr) 2003-01-30
EP1408109A1 (fr) 2004-04-14
US20050288216A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
Mandon et al. Three-dimensional HepaRG spheroids as a liver model to study human genotoxicity in vitro with the single cell gel electrophoresis assay
Kletsas et al. Effect of protein kinase inhibitors on the stretch‐elicited c‐Fos and c‐Jun up‐regulation in human PDL osteoblast‐like cells
Hirrlinger et al. Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells
Chen et al. Quantitative proteomic analysis of the secretory proteins from rat adipose cells using a 2D liquid chromatography− MS/MS approach
Yammani et al. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products
Bu et al. High‐throughput cytochrome P450 (CYP) inhibition screening via a cassette probe‐dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1
García et al. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins
DK1766400T3 (da) Fremgangsmåde til at udföre fuldblodsanalyser
ATE340025T1 (de) Vorrichtungen und verfahren für hochdurchsatz- probenentnahme und analyse
RU2010139426A (ru) Комбинация химического и генетического подходов к получению индуцированных плюрипотентных стволовых клеток
IS7611A (is) Örfylki og aðferð til þess að framkvæma blöndunarhvörf fyrir fjölda sýna á einu örfylki
DE60330248D1 (de) Teststreifen zum analytnachweis und verwendungsverfahren
DK0973943T3 (da) Fremgangsmåder til identificering af nucleinsyresekvenser, der koder midler, som påvirker cellulære fænotyper
EP1427810A4 (fr) Methode et essai de quantification permettant d'evaluer l'etat du systeme c-kit/scf/pakt
DK1229047T3 (da) IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse
Adachi et al. Proteome-wide discovery of unknown ATP-binding proteins and kinase inhibitor target proteins using an ATP probe
Massaccesi et al. Dexamethasone‐induced skeletal muscle atrophy increases O‐GlcNAcylation in C2C12 cells
EP3851856A3 (fr) Procédé, réseau et son utilisation
Huesgen et al. Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease
JP2009539377A5 (fr)
Kjellerup et al. Pro‐inflammatory cytokine release in keratinocytes is mediated through the MAPK signal‐integrating kinases
Thevis et al. Proteases in doping control analysis
DE60228196D1 (de) System und verfahren zur in-vitro-analyse von therapeutischen wirkstoffen
Mendez et al. Predicting small molecule binding pockets on diacylglycerol kinases using chemoproteomics and AlphaFold
Ryan et al. In vitro senescence and senolytic functional assays